May 16th, 20242024-05-16Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection February 26th, 20242024-02-26Championing Rare Voices on Rare Disease Day All News